Background and Objectives The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial. The aim of this study was to correlate the expression of MyAg with clinical, hematologic and biological parameters, and to analyze the impact on response to treatment and prognosis in a large series of adult ALL uniformly characterized and treated. Design and Methods We analyzed the expression of the MyAg CD13 and/or CD33 in a cohort of 377 adult patients with de novo ALL enrolled and treated in the GIMEMA ALL 0496 protocol. Results MyAg expression was documented in 35% of the 377 adult ALL cases analyzed. MyAg were significantly more frequently associated with B-lineage ALL (38%) than with T-ALL (24%) (p=0.02). No difference was found with regard to clinical features at presentation; a difference was found only for white cell count (p=0.03), percentage of peripheral blasts (p=0.004) and platelet count (p=0.004). No difference was observed in the expression of MyAg between patients with normal or abnormal cytogenetics or between those with high-risk (BCR-ABL+, ALL1-AF4+, E2A-PBX1+) or low-risk B-lineage ALL. We failed to observe any difference between MyAg-positive and MyAg-negative cases in terms of achievement of complete remission, disease-free survival and overall survival at 5 years. Interpretation and Conclusions Our data indicate that ALL MyAg expression in adults with ALL is not associated with adverse presenting clinical and biological features, and that response to treatment and prognosis is comparable in MyAg-positive and MyAg-negative ALL patients with regards to both complete remission rate and overall survival. We suppose that these result are due to more intensive treatment modalities adopted in the GIMEMA ALL 0496 protocol.

Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial / A., Vitale; Guarini, Anna; C., Ariola; Meloni, Giovanna; O., Perbellini; M., Pizzuti; C. D., Gregoris; V., Mettivier; A., Pastorini; G., Pizzolo; Vignetti, Marco; Mandelli, Franco; Foa, Roberto. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:3(2007), pp. 342-348. [10.3324/haematol.10385]

Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial

GUARINI, Anna;MELONI, Giovanna;VIGNETTI, Marco;MANDELLI, Franco;FOA, Roberto
2007

Abstract

Background and Objectives The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial. The aim of this study was to correlate the expression of MyAg with clinical, hematologic and biological parameters, and to analyze the impact on response to treatment and prognosis in a large series of adult ALL uniformly characterized and treated. Design and Methods We analyzed the expression of the MyAg CD13 and/or CD33 in a cohort of 377 adult patients with de novo ALL enrolled and treated in the GIMEMA ALL 0496 protocol. Results MyAg expression was documented in 35% of the 377 adult ALL cases analyzed. MyAg were significantly more frequently associated with B-lineage ALL (38%) than with T-ALL (24%) (p=0.02). No difference was found with regard to clinical features at presentation; a difference was found only for white cell count (p=0.03), percentage of peripheral blasts (p=0.004) and platelet count (p=0.004). No difference was observed in the expression of MyAg between patients with normal or abnormal cytogenetics or between those with high-risk (BCR-ABL+, ALL1-AF4+, E2A-PBX1+) or low-risk B-lineage ALL. We failed to observe any difference between MyAg-positive and MyAg-negative cases in terms of achievement of complete remission, disease-free survival and overall survival at 5 years. Interpretation and Conclusions Our data indicate that ALL MyAg expression in adults with ALL is not associated with adverse presenting clinical and biological features, and that response to treatment and prognosis is comparable in MyAg-positive and MyAg-negative ALL patients with regards to both complete remission rate and overall survival. We suppose that these result are due to more intensive treatment modalities adopted in the GIMEMA ALL 0496 protocol.
80 and over; adjuvant; administration /&/ dosage; adolescent; adult; adult all; adult t-cell; aged; antigens; antineoplastic combined chemotherapy protocols; biosynthesis/genetics; blood cell count; blood/drug therapy/metabolism/mortality/radiotherapy; burkitt lymphoma; cd; cd13; cell lineage; cohort studies; combined modality therapy; cranial irradiation; cytarabine; daunorubicin; differentiation; disease-free survival; drug resistance; female; humans; immunophenotyping; leukemia-lymphoma; male; middle aged; multicenter studies as topic; multiple; myeloid antigen; myelomonocytic; neoplasm; precursor cell lymphoblastic leukemia-lymphoma; prognosis; radiotherapy; randomized controlled trials as topic; remission induction; statistics /&/ numerical data; therapeutic use
01 Pubblicazione su rivista::01a Articolo in rivista
Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial / A., Vitale; Guarini, Anna; C., Ariola; Meloni, Giovanna; O., Perbellini; M., Pizzuti; C. D., Gregoris; V., Mettivier; A., Pastorini; G., Pizzolo; Vignetti, Marco; Mandelli, Franco; Foa, Roberto. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:3(2007), pp. 342-348. [10.3324/haematol.10385]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/396593
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 35
social impact